Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin
- 285 Downloads
Background Cyclosporin is a calcineurin inhibitor widely used in renal transplant patients to prevent organ rejection. Several position papers have been published but no reports on the practical experience in pediatric patients undergoing conversion between cyclosporin innovator and generic products are available. Objective To evaluate the pharmacokinetics and safety as part of therapeutic monitoring of cyclosporin in renal transplant pediatric patients who switch from the innovator to the generic formulation in Argentina. Setting Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina. Methods Stable pediatric renal transplant patients (6 months post-transplant) switched from the innovator to the generic formulation of cyclosporin microemulsion capsule. Cyclosporin pharmacokinetic parameters were obtained while taking the innovator and after starting with the generic formulation. Blood samples were drawn before and 1, 2, and 3 h after drug administration and subsequently quantified. Pharmacokinetic parameters were obtained by means of a Bayesian approach. Main outcomes measure Cyclosporin pharmacokinetic parameters (area under the curve, AUC; Blood concentration after 2 h, C2), adverse events and graft rejection. Results A total of 12 patients were included. Median (range) age and time post-transplant were 10.7 years (6.5–17.7) and 8.3 years (3.4–14.0), respectively. Two patients or their parents did not consent to the switch. Median (range) dose normalized cyclosporin AUC and C2 were 1.15 (mg*h/L)/mg/kg (0.72–3.0) and 265.5 (ng/ml)/mg/kg (120.8–725.7), respectively, on the innovator therapy and 1.05 (mg*h/L)/mg/kg (0.54–2.22) and 317.1 (ng/ml)/mg/kg (116.7–564.7) for the generic drug after the switch. The median (range) percentage of change in the AUC and C2 when switching between formulations were 16.7 % (0.7–56.7) and 13.1 % (3.7–68.6), respectively. No significant changes in serum creatinine levels were registered when comparing before and after substitution of products. Adverse events (number of events) recorded 5 months before and after the switch included hirsutism (2), hypertension (2), and gingival hyperplasia (1). Conclusion Conversion of cyclosporin from innovator brand to generic in pediatric renal transplant patients needs to be closely monitored.
KeywordsCyclosporin Generics Pediatrics Pharmacokinetics Renal transplant
The authors would like to thank Dr. Pierre Marquet for the web service offered by the University of Limoges for pharmacokinetic assessment of immunosuppressants and head nurse Victoria Barroca, for technical assistance.
This work was supported by Hospital de Pediatría Prof. Dr. Juan P. Garrahan.
Conflicts of interest
None of the authors present conflict of interest.
- 3.Eljebari H, Ben Fradj N, Salouage I, Gaies E, Trabelsi S, Jebabli N, et al. Estimation of abbreviated cyclosporine A area under the concentration-time curve in allogenic stem cell transplantation after oral administration. J Transplant. 2012; 2012:342701.Google Scholar
- 17.Troncoso P, Ortiz AM, Jara A, Vilches S. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values. Transplant Proc. 2009;41(1):127–30.PubMedCrossRefGoogle Scholar
- 19.NEORAL® Soft Gelatin Capsules (cyclosporine capsules, USP) MODIFIED and NEORAL® Oral Solution (cyclosporine oral solution, USP) MODIFIED. Prescribing Information. NOVARTIS. Reference ID: 3302945. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050715s033,050716s034lbl.pdf. Accessed 10 Feb 2014.
- 20.Certificados de especialidades medicinales emitidos - Monofármacos - Junio 2007. ANMAT. Available from: http://www.anmat.gov.ar/ESPECMED/junio/certificados_monofarmacos_07.asp. Accessed 11 Feb 2014.
- 21.Drugs and money—prices, affordability and cost containment. In: Dukes M, Haaijer-Ruskamp F, de Joncheere C, Rietveld A, editors. World Health Organization. Regional Office for Europe by IOS Press; 2003. pp. 137–149. ISBN 1 58603 334 4.Google Scholar
- 33.Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varni JW, et al. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr. 2012;160(5):820–6.PubMedCrossRefGoogle Scholar
- 35.Miranda I, Cherato M, Onofri A. Cobertura social para trasplantados subsidados por CUCAIBA en la red estatal. Available from: http://www.cucaiba.gba.gov.ar/019.htm. Accessed 12 Feb 2014.
- 36.Calabria A. Analyzing the market for organs donation: evaluation of the introduction of incentives in Argentina. MPRA Paper No. 36044. 2011. Available from: http://mpra.ub.uni-muenchen.de/36044/1/MPRA_paper_36044.pdf. Accessed 12 Feb 2014.
- 38.Drug interactions. Micromedex Solutions. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.ShowDrugInteractionsResults. Accessed 14 Feb 2014.